vs

Side-by-side financial comparison of Hyperscale Data, Inc. (GPUS) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $26.9M, roughly 1.4× Hyperscale Data, Inc.). Hyperscale Data, Inc. runs the higher net margin — -112.0% vs -161.8%, a 49.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 38.4%). Hyperscale Data, Inc. produced more free cash flow last quarter ($-56.2M vs $-71.3M).

Hyperscale Data, Inc. provides GPU-accelerated computing infrastructure and cloud solutions tailored for AI development, big data processing, and high-performance computing workloads. It primarily serves AI startups, large technology firms, and cloud service providers across North America and the Asia-Pacific region, delivering scalable, high-efficiency computing resources to support complex data processing needs.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

GPUS vs IBRX — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.4× larger
IBRX
$38.3M
$26.9M
GPUS
Growing faster (revenue YoY)
IBRX
IBRX
+368.6% gap
IBRX
407.0%
38.4%
GPUS
Higher net margin
GPUS
GPUS
49.8% more per $
GPUS
-112.0%
-161.8%
IBRX
More free cash flow
GPUS
GPUS
$15.1M more FCF
GPUS
$-56.2M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GPUS
GPUS
IBRX
IBRX
Revenue
$26.9M
$38.3M
Net Profit
$-30.1M
$-61.9M
Gross Margin
14.5%
99.0%
Operating Margin
-117.8%
-169.0%
Net Margin
-112.0%
-161.8%
Revenue YoY
38.4%
407.0%
Net Profit YoY
-6670.3%
-4.7%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GPUS
GPUS
IBRX
IBRX
Q4 25
$26.9M
$38.3M
Q3 25
$24.3M
$32.1M
Q2 25
$25.9M
$26.4M
Q1 25
$25.0M
$16.5M
Q4 24
$19.4M
$7.6M
Q3 24
$31.1M
$6.1M
Q2 24
$17.8M
Q1 24
$38.4M
Net Profit
GPUS
GPUS
IBRX
IBRX
Q4 25
$-30.1M
$-61.9M
Q3 25
$-13.0M
$-67.3M
Q2 25
$-19.1M
$-92.6M
Q1 25
$-4.2M
$-129.6M
Q4 24
$-445.0K
$-59.2M
Q3 24
$-25.5M
$-85.7M
Q2 24
$-33.9M
Q1 24
$3.7M
Gross Margin
GPUS
GPUS
IBRX
IBRX
Q4 25
14.5%
99.0%
Q3 25
25.8%
99.4%
Q2 25
23.7%
99.5%
Q1 25
21.1%
99.6%
Q4 24
6.5%
Q3 24
27.5%
Q2 24
-21.3%
Q1 24
47.4%
Operating Margin
GPUS
GPUS
IBRX
IBRX
Q4 25
-117.8%
-169.0%
Q3 25
-57.8%
-173.5%
Q2 25
-39.2%
-269.8%
Q1 25
-25.5%
-390.1%
Q4 24
-46.8%
-919.0%
Q3 24
-79.2%
-1314.3%
Q2 24
-151.4%
Q1 24
9.5%
Net Margin
GPUS
GPUS
IBRX
IBRX
Q4 25
-112.0%
-161.8%
Q3 25
-53.5%
-209.8%
Q2 25
-73.7%
-350.3%
Q1 25
-16.8%
-784.9%
Q4 24
-2.3%
-783.4%
Q3 24
-82.3%
-1404.0%
Q2 24
-190.7%
Q1 24
9.7%
EPS (diluted)
GPUS
GPUS
IBRX
IBRX
Q4 25
$-0.06
Q3 25
$-0.39
$-0.07
Q2 25
$-2.66
$-0.10
Q1 25
$-0.15
Q4 24
$-8.78
$-0.08
Q3 24
$-24.82
$-0.14
Q2 24
$-37.81
Q1 24
$3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GPUS
GPUS
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$13.1M
$242.8M
Total DebtLower is stronger
$83.1M
Stockholders' EquityBook value
$119.8M
$-500.5M
Total Assets
$313.7M
$501.9M
Debt / EquityLower = less leverage
0.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GPUS
GPUS
IBRX
IBRX
Q4 25
$13.1M
$242.8M
Q3 25
$24.8M
$257.8M
Q2 25
$5.9M
$153.7M
Q1 25
$4.2M
$61.6M
Q4 24
$4.5M
$149.8M
Q3 24
$7.9M
$130.4M
Q2 24
$9.6M
Q1 24
$18.9M
Total Debt
GPUS
GPUS
IBRX
IBRX
Q4 25
$83.1M
Q3 25
$80.0M
Q2 25
$88.5M
Q1 25
$92.8M
Q4 24
$96.7M
Q3 24
$104.8M
Q2 24
$106.8M
Q1 24
$30.0M
Stockholders' Equity
GPUS
GPUS
IBRX
IBRX
Q4 25
$119.8M
$-500.5M
Q3 25
$55.9M
$-524.3M
Q2 25
$5.5M
$-570.7M
Q1 25
$6.3M
$-591.4M
Q4 24
$8.6M
$-489.1M
Q3 24
$2.7M
$-745.1M
Q2 24
$26.7M
Q1 24
$59.0M
Total Assets
GPUS
GPUS
IBRX
IBRX
Q4 25
$313.7M
$501.9M
Q3 25
$242.4M
$519.0M
Q2 25
$213.5M
$402.1M
Q1 25
$218.5M
$303.8M
Q4 24
$220.8M
$382.9M
Q3 24
$231.5M
$364.6M
Q2 24
$270.8M
Q1 24
$299.8M
Debt / Equity
GPUS
GPUS
IBRX
IBRX
Q4 25
0.69×
Q3 25
1.43×
Q2 25
16.06×
Q1 25
14.71×
Q4 24
11.19×
Q3 24
38.41×
Q2 24
4.00×
Q1 24
0.51×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GPUS
GPUS
IBRX
IBRX
Operating Cash FlowLast quarter
$-37.7M
$-70.4M
Free Cash FlowOCF − Capex
$-56.2M
$-71.3M
FCF MarginFCF / Revenue
-208.7%
-186.2%
Capex IntensityCapex / Revenue
68.6%
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-87.1M
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GPUS
GPUS
IBRX
IBRX
Q4 25
$-37.7M
$-70.4M
Q3 25
$-17.8M
$-68.9M
Q2 25
$-3.1M
$-79.7M
Q1 25
$-4.0M
$-85.9M
Q4 24
$-9.2M
$-85.1M
Q3 24
$3.7M
$-98.8M
Q2 24
$-3.7M
Q1 24
$-10.2M
Free Cash Flow
GPUS
GPUS
IBRX
IBRX
Q4 25
$-56.2M
$-71.3M
Q3 25
$-20.6M
$-69.6M
Q2 25
$-3.5M
$-80.8M
Q1 25
$-6.8M
$-87.0M
Q4 24
$-9.3M
$-87.3M
Q3 24
$2.6M
$-101.6M
Q2 24
$-5.9M
Q1 24
$-11.6M
FCF Margin
GPUS
GPUS
IBRX
IBRX
Q4 25
-208.7%
-186.2%
Q3 25
-84.5%
-217.2%
Q2 25
-13.5%
-305.9%
Q1 25
-27.3%
-526.9%
Q4 24
-47.6%
-1155.4%
Q3 24
8.4%
-1663.2%
Q2 24
-33.4%
Q1 24
-30.3%
Capex Intensity
GPUS
GPUS
IBRX
IBRX
Q4 25
68.6%
2.4%
Q3 25
11.5%
2.3%
Q2 25
1.5%
4.1%
Q1 25
11.5%
6.8%
Q4 24
0.3%
28.0%
Q3 24
3.6%
45.7%
Q2 24
12.6%
Q1 24
3.7%
Cash Conversion
GPUS
GPUS
IBRX
IBRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-2.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GPUS
GPUS

Transferred Over Time$10.4M39%
Revenue From Mined Crypto Assets At Sentinum Owned And Operated Facilities$5.8M21%
Hotel And Real Estate Operations$4.8M18%
Other$4.0M15%
Turn On Green$2.0M7%

IBRX
IBRX

Segment breakdown not available.

Related Comparisons